Getafe

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.

Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 on kidney function in adults with chronic kidney disease, some of whom may also have type 2 diabetes, and who are living with overweight or obesity. The study compares NNC0519-0130 with semaglutide, an existing medicine, and a placebo, which is a "dummy" treatment. This is a Phase 2 proof-of-concept and dose-finding study aimed at understanding how these treatments may reduce kidney damage. Participants will be randomly assigned to one of three groups receiving either NNC0519-0130, semaglutide, or placebo. All treatments are given by subcutaneous injection once weekly. The study treatment phase lasts up to 36 weeks, with assessments at weeks 12, 24, and 36 to monitor changes in kidney damage by measuring the urinary albumin-to-creatinine ratio. The overall study duration can be up to 43 weeks. During the study, participants will be regularly monitored through laboratory tests and clinical evaluations to assess kidney function and safety. Researchers will measure changes from the start of the study in the urinary albumin-to-creatinine ratio at multiple time points. Participants will also need to have stable doses of certain blood pressure medications before joining. Safety and treatment effects will be assessed throughout the study period.

Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine (20vPnC) protects adults aged 65 and older who are hospitalized with radiologically-confirmed community-acquired pneumonia (RAD+CAP). The study focuses on pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria included in the 20vPnC vaccine. This observational study uses a test-negative design to compare the presence of these specific bacterial types in vaccinated and non-vaccinated participants. Participants provide a urine sample that is tested with BinaxNOW4 S. pneumoniae and serotype-specific urinary antigen detection (UAD) assays to detect the bacteria and its strains. Cases are defined as participants with pneumonia caused by the seven additional serotypes in 20vPnC beyond those in the 13-valent vaccine, plus serotype 15C. Controls include participants without these vaccine serotypes or with pneumonia caused by other agents. The main diagnostic procedure is the non-invasive urine test, and all participants are hospitalized adults aged 65 or older with pneumonia confirmed by chest imaging. Participants share demographic and medical history information and undergo urine testing during their hospital stay, which typically lasts 1 to 2 days for study procedures. Researchers collect data on illness and hospitalization for up to 30 days through medical chart reviews. The primary outcome measures how effective 20vPnC is against pneumonia caused by the additional serotypes over a 55-month period, helping to understand the vaccine's real-world performance in this older population.

Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy (IgAN), a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, causing protein to appear in the urine. The study aims to understand how felzartamab influences proteinuria and kidney function, while also assessing the safety and how the body processes this treatment. This is a Phase 3, randomized, double-blind, placebo-controlled study focusing on adults with IgAN. Participants will be randomly assigned to receive either felzartamab or a placebo through intravenous (IV) infusions. Neither the participants nor the researchers will know which treatment is given. The treatment period lasts 24 weeks followed by an 80-week follow-up period. In total, participants will attend 17 study visits over about 2 years to receive infusions and participate in study activities. During the study, participants will undergo assessments including urine tests to measure protein levels, kidney function evaluations, and safety monitoring. Researchers will track changes in proteinuria from the start of the study to Week 36 as the main outcome. Additional measurements will include kidney function, clinical endpoints, and the study of how felzartamab is processed by the body. Participant safety and long-term effects will be monitored throughout the study and follow-up periods.

Intensive care units (ICUs) are essential parts of modern healthcare, providing specialized care for critically ill patients with severe conditions. These units focus on comprehensive treatment for patients with organ dysfunction who need high-level care, advanced technology, and support from various medical specialties. Since the late 1950s, ICUs have evolved with scientific advances, especially in mechanical ventilation strategies, improving patient outcomes over time. This study aims to analyze changes in patient outcomes, including mortality, in an 18-bed medical-surgical ICU from 1991 through 2026. It assesses how care practices and patient case-mix have evolved over 35 years, particularly focusing on patients needing mechanical ventilation and other intensive interventions. Participants admitted to the ICU will be observed for outcomes like intensive care unit mortality at 180 days. The study collects data over many years to evaluate long-term trends in patient survival and care effectiveness. This research helps understand how improvements in ICU practices have influenced patient outcomes across decades.

Researchers are studying patients who have had a myocardial infarction (heart attack), focusing on those with non-obstructive coronary arteries (MINOCA), a condition where the cause is often unclear. The study compares these patients with those who have obstructive coronary arteries (MICAD) to evaluate inflammation and endothelial dysfunction using specific biomarkers during both the acute and stable phases of their condition. Participants undergo a coronary angiography (coronariography) to classify them as either MICAD or MINOCA based on the presence or absence of significant artery narrowing. Levels of biomarkers including interleukin-6, tumor necrosis factor-alpha, high-sensitivity C-reactive protein, and asymmetric dimethylarginine are measured at three key times: within 24 hours of pain onset, at hospital discharge, and two months after the heart attack. The study also assesses the relationship between these biomarkers and the risk of MINOCA. During the study, participants will have blood samples taken at the specified times to measure inflammation and endothelial dysfunction markers. Researchers will analyze how these measurements relate to heart damage and patient outcomes. The study aims to improve understanding of MINOCA by monitoring these biomarkers over time, helping to identify differences between MINOCA and MICAD patients.

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are studying the effects of continued nutritional support after hospital discharge for adult medical patients who are at nutritional risk due to malnutrition. This research aims to compare ongoing post-discharge nutritional support to usual care home nutrition and assess its impact on mortality, frailty, functional outcomes, and recovery. The study builds on earlier findings that nutritional support during hospital stays reduces complications and mortality, but long-term benefits after discharge remain unclear. Participants receive individualized nutritional plans supervised by experienced dietitians, including the daily use of specific oral nutritional supplements with high energy and protein content such as Resource Ultra and Resource 2.0 (Fibre). The plan may be adjusted based on patient preferences, including options like between meal snacking and food enrichment. General nutritional information about healthy food behavior is also provided upon hospital discharge. Follow-up phone calls occur every 2 to 4 weeks to monitor and support adherence to the nutritional intervention. During the study, participants are closely monitored for outcomes including time to death from any cause over a three-year period. Researchers will evaluate frailty, functional recovery, and overall health status. The study involves ongoing assessments and follow-ups to understand how long-term nutritional support influences disease progression and recovery. Participants' adherence to the nutritional plans is supported and tracked through regular dietitian contact and supplement use.

Researchers are investigating the effects of different doses of dexamethasone, a corticosteroid, in adults with acute hypoxemic respiratory failure (AHRF) caused by infections, including COVID-19. This condition ranges from mild respiratory illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The trial aims to clarify whether moderate doses of dexamethasone reduce mortality more than low doses in patients requiring mechanical ventilation in intensive care units. Participants will be randomly assigned to receive intravenous dexamethasone either at a low dose of 6 mg per day for 10 days or a higher dose regimen of 20 mg per day for 5 days followed by 10 mg per day for another 5 days. This is a randomized, controlled, open-label study conducted across multiple centers in Spain. The study focuses on patients who are mechanically ventilated with confirmed pulmonary or systemic infections causing AHRF or ARDS. During the study, researchers will monitor patients for 60-day mortality as the main outcome and assess the number of days they are free from mechanical ventilation within 28 days. The study follows the intention-to-treat principle, ensuring all randomized patients are analyzed according to their assigned treatment. The trial includes detailed clinical assessments, chest imaging, and oxygenation measurements as part of patient evaluation throughout the treatment period.

Researchers are exploring the use of a computational ecosystem called MOTIVA to support an autonomous exercise program aimed at promoting healthy aging in community-dwelling older adults who are robust or prefrail. The study focuses on older adults aged 70 or above with signs of frailty, aiming to improve their independence as well as their physical and cognitive health while reducing the use of healthcare resources. The program emphasizes personalized motivational support tailored to the individual's current stage in behavior change to help prevent abandonment and improve adherence to exercise. The MOTIVA ecosystem provides a personalized exercise plan based on each participant's motivational profile and performance without requiring supervision by healthcare professionals or caregivers. This approach allows participants to engage in an unsupervised exercise program adapted to their abilities and motivational needs. The study treatment lasts for 12 months, during which participants follow the tailored exercise plan independently. Participants will be assessed for functional and performance abilities during the study, with ongoing motivational support integrated into the ecosystem. The main outcome measured is the use and effectiveness of the MOTIVA ecosystem from enrollment through the end of the 12-month treatment period. The study includes regular monitoring of participant progress and adherence to the exercise plan to evaluate its impact on healthy aging outcomes.